Dapagliflozin Extends Lifespan Without SGLT2 — A Hidden Target Revealed
In worms lacking SGLT2, dapagliflozin still prolongs lifespan and blocks glucose uptake — pointing to a novel molecular target with big implications.
Summary
Dapagliflozin, a popular diabetes and heart failure drug, is known to work by blocking the SGLT2 glucose transporter in the kidney. But researchers used the worm C. elegans — which has no SGLT2 — to test whether the drug has other mechanisms. Remarkably, dapagliflozin still extended lifespan and altered gene expression in ways that mirrored mammalian studies. It also reduced glucose uptake in the worms. When scientists silenced a sodium-dependent multivitamin transporter called SMVT-1, the drug's glucose-blocking effect disappeared. This suggests SMVT-1 may be an alternative target through which flozins exert their broad benefits — including in the heart, where SGLT2 is absent — opening new avenues for understanding and expanding the therapeutic potential of this drug class.
Detailed Summary
Flozins like dapagliflozin have become cornerstone drugs not just for type 2 diabetes but for heart failure and chronic kidney disease. The puzzle: the heart doesn't express SGLT2, so why do these drugs help cardiac patients? Researchers suspected off-target mechanisms but lacked a clean experimental system to identify them.
To solve this, the team turned to C. elegans, a tiny worm used extensively in aging research. Crucially, C. elegans has no SGLT2 orthologue, making it an ideal model to isolate SGLT2-independent effects. Glucose-fed worms were treated with dapagliflozin, then assessed for lifespan, gene expression, and glucose transport using a fluorescent glucose analogue.
The results were striking. Despite lacking SGLT2, dapagliflozin significantly extended worm lifespan under glucose-fed conditions — mirroring findings from mouse studies. Transcriptomic profiling showed gene expression changes closely resembling those seen in mammalian systems treated with the same drug. In vivo glucose uptake was measurably reduced by dapagliflozin.
The most mechanistically novel finding involved SMVT-1, the worm orthologue of the sodium-dependent multivitamin transporter. When SMVT-1 expression was knocked down, dapagliflozin's glucose transport inhibition was abolished — directly implicating this transporter as a functionally relevant off-target. SMVT transports biotin, pantothenate, and lipoic acid, and its inhibition could have downstream metabolic consequences worth exploring.
These findings have real implications for longevity medicine. They suggest flozins may extend healthspan through mechanisms broader than SGLT2 inhibition alone, potentially explaining cardiovascular and renal benefits. They also raise the possibility of designing next-generation flozin-like compounds that specifically leverage these alternative pathways. Caveats include the evolutionary distance between worms and humans, and that the full paper was not available for review — the summary is based on the abstract only.
Key Findings
- Dapagliflozin extended C. elegans lifespan even though the worm lacks any SGLT2 orthologue.
- The drug reduced glucose uptake in vivo in worms, demonstrating SGLT2-independent glucose transport inhibition.
- Knocking down SMVT-1 (sodium-dependent multivitamin transporter) abolished dapagliflozin's glucose-blocking effect.
- Worm transcriptomic profiles under dapagliflozin closely resembled gene expression changes seen in mammalian models.
- Findings suggest off-target mechanisms may explain flozins' cardiac and kidney benefits where SGLT2 is absent.
Methodology
Researchers used C. elegans — which naturally lacks an SGLT2 orthologue — as a clean genetic model to isolate off-target flozin effects. Glucose-fed worms received dapagliflozin treatment; outcomes included lifespan curves, transcriptomic profiling, and in vivo glucose uptake measured with the fluorescent analogue 2-NBDG. SMVT-1 was knocked down via RNA interference to assess its functional role.
Study Limitations
C. elegans is evolutionarily distant from humans, so findings require validation in mammalian cardiac and renal systems before clinical conclusions can be drawn. The specific SMVT mechanism needs confirmation in human cell lines and animal models. This summary is based on the abstract only, as the full paper was not available open access.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: